Skip to main content
Premium Trial:

Request an Annual Quote

Xceed Molecular Licenses Moffitt Gene Signature for Colon Cancer Dx Research

NEW YORK (GenomeWeb News) – Xceed Molecular has licensed the rights to use a gene signature for colon cancer from the Moffitt Cancer Center, the company said today.
 
The Wellesley, Mass.-based firm has purchased the worldwide, exclusive rights to use the gene signature to develop a molecular test that can predict patient prognosis for the disease, which Xceed said is diagnosed in over 100,000 Americans each year. Xceed will work with Tampa, Fla.-based Moffitt researchers to complete clinical development and validation of the signature, which uses biopsy tissues from colonoscopy to predict the chances of return of the disease.
 
The collaborators hope to develop a list of genes that Xceed will include in its TipChip colon cancer microarray device that runs on the company’s Ziplex System. Xceed said that it will run the first samples in its Expression Services Lab in Toronto to optimize the performance of the signature on the Ziplex System. The company also will provide Moffitt with a Ziplex for additional validation studies.
 
“We have high hopes that the gene signature that we are developing may be useful in helping physicians to make critical treatment decisions, but the great challenge in this field has been turning promising biomarkers into routine diagnostic tools,” Tim Yeatman, a Moffitt researcher who helped develop the colon cancer gene signature, said in a statement.
 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more